hotspot -WSS

hotspot

author：entertainment 2025-09-02 22:07:58 - browse：7835

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

hotspot

WSS

What causes an itch? Researchers may have solved the mystery

Teach medical students about patients with intellectual disabilities

New Ultima Genomics DNA sequencer can read genome for $100

Leukemia patients are helped by Syndax's new type of therapy

Pfizer plans to depart BIO

STAT letters to the editor on burnt

entertainment

hotspot

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Biden administration opens offers in Medicare drug price negotiations

Drug repurposing or repositioning? The language matters

Why sickle cell disease is getting the first CRISPR treatment

Cancer drug shortages should be causing more outrage

Vertigo drug brings hope for rare neuron disorder, Niemann

In Memoriam: Notable people who died in 2023

Cognito secures funding to test medical device for Alzheimer's

The cancer drug shortage isn’t new — and neither are the solutions

Congressmen charge Covid hearing ‘could have been an email’

hotspot

Pregnancy discrimination could be enabled by AI

Woodcock on FDA’s accelerated approval and her next chapter

Biden administration opens offers in Medicare drug price negotiations

Novo Nordisk to expand supply of Wegovy for U.S. patients

Vertex non

New Ultima Genomics DNA sequencer can read genome for $100

hotspot

entertainment

Wikipedia

knowledge